Center for Genomic Integrity

유전체 항상성 연구단

관련기사 바로가기
유전체 항상성 연구단

DNA is the building block for the genome and provides the blueprint for almost every aspect of life. DNA can be damaged by endogenous assaults such as replication errors, oxidative stress or by exogenous challenges such as radiation or toxic chemicals. Failure to repair such damage results in cell death or the accumulation of changes in DNA that can cause genetic diseases including cancers or can lead to premature aging. Research at the IBS Center for Genomic Integrity focused on molecular mechanisms of the many DNA damage response and repair pathways Finally, we develop small molecule modulators or CRISPR-Cas9 to control DNA repair pathways to exploit vulnerabilities of tumors in therapeutic settings.

Major research field

CRISPR Synthetic lethality, DNA Repair, DNA Recombination, DNA Damage Response, Cancer, Aging

Desired field of research

DNA Repair, Synthetic lethality, Cancer, DNA Damage Response, ATAD5, PCNA, CRISPR, CRISPR-Cas9

Research Keywords and Topics

• Composition For Inducing Apoptosis of Cancer Cell And Method For Inducing Apoptosis of Cancer Cell Using the Same
• Molecular Analysis of DNA replication, repair, recombination genes and proteins
• Cellular Response to DNA damaging agents
• Animal models to understand defects in DNA replication, repair, recombination
• Identification of potential precision therapeutic molecules for cancers and aging

Research Publications
MORE

• Nucleic Acid Res. MSH2-MSH3 promotes DNA end resection during HR and blocks TMEJ through interaction with SMARCAD1 and EXO1 (2023)
• Nature Communication. Regulation of the BRCA1 stability through the UBS domain of isoleucyl-tRNA synthetase. (2022)
• PNAS. Precisiion cell death of tumors by targeting InDel mutations by CRISPR-Cas9. (2022)
• Nature Cell Biol. Haematopoietic stem cell-dependent Notch transcription is mediated by p53 through the histone chaperone Supt16h. (2020)

Patents

• Korean patent (10-2021-0108KR) Application of 2-chloro-N,N-diethylmethylamine hydrochloride for improving cancer treatment with PARP inhibitor.
• Korean patent (10-2020-0081538) 유전자가 변이된 세포의 사멸 유도 조성물 및 상기 조성물을 이용한 유전자가 변형된 세포 사멸 유도 방법
• Korean Patent No. (10-2019-0157333) Development of synthetic Baicalein derivatives as a chemotherapeutic agent
• U.S. Patent No. 61/930,291 (E-039-2014/0-US-01) Compounds and Method for treating PARP1-deficient cancers

국가과학기술표준분류

  • LA. 생명과학
  • LA01. 분자세포생물학
  • LA0199. 달리 분류되지 않는 분자세포 생물학

국가기술지도분류

  • 건강한 생명사회 지향
  • 021600. 유전자조작/전달기술

녹색기술분류

  • 녹색기술관련 과제 아님
  • 녹색기술관련 과제 아님
  • 999. 녹색기술 관련과제 아님

6T분류

  • BT 분야
  • 기초/기반기술
  • 020114. 생명현상 및 기능연구